Femasys has received US Food and Drug Administration (FDA) clearance for its FemChec pressure management device, designed to deliver a low-pressure hysterosalpingography as a confirmation test following sterilisation surgery.

FemChec uses patent-pending technology that limits the applied intrauterine pressure to 200 mmHg, allowing physicians to meet the requirements of the mandatory hysterosalpingography confirmation test, while minimising improperly performed tests and procedure complications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Femasys president and CEO Kathy Lee-Sepsick said the FemChec provides benefits to the physician and patient as a properly performed low-pressure confirmation test is critical to relying on the permanent sterilisation procedure long-term.

The company expects to market the first device in the US in December 2011.